Spero Therapeutics Inc (SPRO) delivered earnings and revenue surprises of 9.63% and -49.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., March 16, 2020 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spero Therapeutics, Inc. ("Spero" or "the Company") ...

Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Scott Jackson to its Board of Directors, effective as of today. Mr. Jackson has more than thirty years of corporate leadership experience within the pharmaceutical and biotechnology industry, most recently serving as the Chief Executive Officer and a member of the Board of Directors of Celator Pharmaceuticals, Inc. until it was acquired by Jazz Pharmaceuticals plc.

It's been a mediocre week for Spero Therapeutics, Inc. (NASDAQ:SPRO) shareholders, with the stock dropping 12% to...

Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). “Completing enrollment of ADAPT-PO is a significant milestone in the development of tebipenem HBr,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

SPRO earnings call for the period ending March 31, 2020.

CAMBRIDGE, Mass., May 04, 2020 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option for additional committed funding pursuant to its existing contract with Spero. Specifically, the option exercise provides Spero with $15.9 million in reimbursement for the further development of tebipenem HBr. Spero’s lead product candidate, tebipenem HBr, is an oral carbapenem currently being evaluated in a pivotal Phase 3 clinical trial for the treatment of complicated urinary tract infections (cUTI), with top-line data expected in the third quarter of 2020.

Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for oral SPR720 for the treatment of nontuberculous mycobacterial (NTM) infection. “We are happy to receive this important designation from the FDA, which highlights the critical unmet need that SPR720 is being developed to address,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics.

As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. (SPRO).

CAMBRIDGE, Mass., March 05, 2020 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pomerantz LLP is investigating claims on behalf of investors of Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Spero and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

CAMBRIDGE, Mass., April 30, 2020 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today commenced its previously announced rights offering to raise gross proceeds of $30.0 million (the “Rights Offering”). The subscription rights may be exercised any time during the subscription period of February 11, 2020 through 5:00 p.m., New York time, on March 2, 2020.

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -21.10% and 2.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the first quarter ended March 31, 2020 and provided a business update. The ADAPT-PO trial is comparing an all oral regimen of tebipenem HBr with an existing standard of care intravenous (IV) antibiotic treatment, ertapenem, in patients with cUTI or acute pyelonephritis, randomized 1:1 in each arm.

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) Inc on Monday, setting a price target of $28, which is approximately 137.69% above the present share price of $11.78.

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.